Neutec
Drug Discovery · Generic Drugs
Overview
Neutec is a Turkish pharmaceutical company that prioritises research and development and takes a leading role in discovering new treatment methods and developing medicines. Its R&D department includes a formulation development team working with lab-scale and pilot production equipment on solid, semi-solid and liquid forms. The company is headquartered in Istanbul, Turkey.
Jobs
Apply
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Backend
100% ▲
Tech stack
Technologies named in job postings at Neutec over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
43/100
Practices & domains
GLP
Sign in to see how your skills match this stack
Sign In
News
Neutec Group Guides Buyers From Product Discovery to Product Validation With Bioz Badges
PALO ALTO, CA / ACCESS Newswire / October 21, 2025 / Bioz, Inc. , a pioneering AI platform changing the way companies present research-backed product evidence, is proud to announce a new partnership withNeutec Group . With the addition ofBioz Badgeson ...
Read more
Report
Report
Takeda to obtain select portfolio from Neutec to enhance its business in Turkey
Takeda to obtain select portfolio from Neutec to enhance its business in Turkey
Read more
Report
Takeda to Acquire Select Portfolio from Neutec, Significantly Enhancing its Business in Turkey
Read more
Report
Novartis agrees NeuTec takeover deal
Two Manchester University professors are set for a windfall after the Swiss drugs giant Novartis today agreed to buy their biotech firm for £305m.
Read more
Report
Novartis acquires NeuTec for $569 million
Swiss pharmaceutical giant Novartis has agreed to buy British firm NeuTec Pharma , a specialist in fighting hospital superbugs…
Read more
Report
Novartis makes offer for NeuTec Pharma, acquisition adds two highly promising biotech drugs to portfolio for patients with severe infections
June 7, 2006 , , , , Public offer to acquire 100% of UK specialty biopharmaceutical company for GBP 10.50 per share; total equity consideration of GBP 305 million (USD 569 million), , o Tran...
Read more
Report
NeuTec trials anti-MRSA drug
BIOTECH firm Neutec Pharma, which develops antibodies to treat infectious diseases, is conducting clinical trials across Europe for Aurograb, a drug designed to combat MRSA.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Istanbul
Istanbul
Turkey
HQ
1 open roles 1 posted in 90 days 100% engineering
hires for Backend